Comparative Study of the Effect of Two Doses of Mometasone Furoate Dry Powder Inhaler 200 mcg and 400 mcg QD PM, Fluticasone Propionate 250 mcg BID, and Montelukast 10 mg QD PM, on Bone Mineral Density in Adults With Asthma.

Trial Profile

Comparative Study of the Effect of Two Doses of Mometasone Furoate Dry Powder Inhaler 200 mcg and 400 mcg QD PM, Fluticasone Propionate 250 mcg BID, and Montelukast 10 mg QD PM, on Bone Mineral Density in Adults With Asthma.

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Mometasone (Primary) ; Fluticasone propionate; Montelukast
  • Indications Asthma
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 08 Nov 2011 Results assessing femoral neck and total femur bone mineral density presented at the 2011 Annual Meeting of the American College of Allergy, Asthma and Immunology.
    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database, EudraCT2004-002930-21).
    • 26 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top